Please assess the completion status of the following clinical trial:

Trial Title: KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent; willing and able to complete all required procedures of study.~2. With advanced-stage or metastatic tumor (unresectable) and experienced progression since last anti-tumor treatment; standard therapy is not available or rejected.~3. Subjects must have at least one measurable lesion in advanced solid tumors, at least one measurable or assessable lesion in NK/T cell lymphoma.~4. ECOG performance status of 0 or 1.~5. Subject must have adequate organ function.~6. Female patients and males with partners of childbearing potential should be using highly effective contraceptive measures (failure rate of less than 1% per year). Contraception should be continued for a period of 24 weeks after dosing has been completed.~7. Ability to comply with treatment, procedures and PK sample collection and the required study follow-up procedures.~Exclusion Criteria:~1. Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.~2. Is currently participating or has participated in a study of an investigational drug within 4 weeks prior to the first dose of trial treatment.~3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment.~4. Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.~5. Subjects with active autoimmune diseases or history of autoimmune diseases should be excluded.~6. Active HBV or HCV infection.~7. Known HIV infection or known history of acquired immune deficient syndrome (AIDS).~8. Any unresolved CTCAE Grade ≥ 2 toxicities from prior anti-cancer therapy with the exception of vitiligo, alopecia.~9. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KN046 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).